Arvinas Inc. (ARVN)
ARVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$6.84
-8.19% on the day
Market cap
$447.2M
Small cap
Revenue · 2025
$262.6M
-0.3% on 2024
Net income · 2025
-$81.0M
-30.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ARVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001655759 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $262.6M |
| Net income | -$81.0M |
| Operating income | -$118.5M |
| Net margin | -30.8% |
| Operating margin | -45.1% |
| Revenue growth | -0.3% |
| Cash | $142.9M |
| Total assets | $717.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2023-12-08 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 599 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.8% |
| 1 month | -17.7% |
| 3 months | -15.4% |
| Year to date | -42.7% |
| 1 year | -30.7% |
| From 52-week high | -50.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RZLT | Rezolute Inc. Common Stock (NV) | $4.61 | -5.34% | $445.9M |
| KMDA | Kamada Ltd. | $7.69 | -1.91% | $443.8M |
| NGNE | Neurogene Inc. Common Stock | $21.56 | -11.78% | $431.4M |
| PRTA | Prothena Corporation plc | $8.36 | -0.83% | $429.2M |
| OVID | Ovid Therapeutics Inc. | $2.19 | -9.13% | $427.7M |
| OCS | Oculis Holding AG | $7.62 | -3.30% | $469.3M |
| ALT | Altimmune Inc. | $2.43 | -5.08% | $472.7M |
| DMAC | DiaMedica Therapeutics Inc. | $7.82 | -4.63% | $421.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier